Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference

Stock News

Oct 27

ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1100490684"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100490684\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100490684?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100490684","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference","media":"Stock News","content":"<p>ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | ABBISKO-B (02256) Surges Over 7% Amid Presentation of Pimicotinib Phase III Study Data at 2025 ESMO Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-27 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"","article_id":"1100490684","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100490684","pubTimestamp":1761530770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"III":"信息服务","02256":"和誉-B","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4134":"信息科技咨询与其它服务"},"translate_title":"港股动向|2025年ESMO会议公布皮米替尼III期研究数据，和必拓-B(02256)大涨超7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"02256":1},"content_text":"ABBISKO-B (02256) experienced a rise of over 7% during trading, currently up 6.06% at HKD 15.03, with a trading volume of HKD 9.1686 million. In recent news, ABBISKO-B announced that its subsidiary, Shanghai ABBISKO Biopharmaceutical Technology Co., Ltd. (ABBISKO Pharmaceuticals), has presented long-term efficacy and safety data from the global Phase III MANEUVER study of pimicotinib (ABSK021) for patients with tenosynovial giant cell tumor (TGCT) in a verbal report at the 2025 European Society for Medical Oncology (ESMO) conference. Pimicotinib has been prioritized for review by the National Medical Products Administration (NMPA) of China for adult patients with TGCT requiring systemic treatment and has also received Breakthrough Therapy Designation (BTD) from the NMPA. Additionally, pimicotinib holds a BTD from the U.S. Food and Drug Administration (FDA) and has been granted Priority Medicines (PRIME) designation by the European Medicines Agency (EMA).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}